A multicentre retrospective comparison of central nervous system prophylaxis strategies among patients with high-risk diffuse large B-cell lymphoma
Chan Y. Cheah(The University of Western Australia), John F. Seymour(The Royal Melbourne Hospital), H. Miles Prince(Peter MacCallum Cancer Centre), Constantine S. Tam(The Alfred Hospital), Kate Burbury(The University of Melbourne), Glen Kennedy(Royal Brisbane and Women's Hospital), M. Wolf(Peter MacCallum Cancer Centre), Pasquale L. Fedele(Monash Health), Alexander George(Peter MacCallum Cancer Centre), Michael Gilbertson(Monash Health), David Ritchie(Peter MacCallum Cancer Centre), Kacey O’Rourke(Royal Brisbane and Women's Hospital), Stephen Opat(Monash Health), Simon J. Harrison(Peter MacCallum Cancer Centre), Michael Dickinson(The University of Melbourne), David Westerman(University of Melbourne), Kirsten Herbert(Peter MacCallum Cancer Centre), Dennis Carney(The University of Melbourne), E. Januszewicz(Peter MacCallum Cancer Centre), Soo‐Yong Tan(Monash Health)
Cited by 132
Related Papers
ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets
|Nature Medicine|2013|3k
Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2015|1.9k
iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL
|Blood|2018|1.7k
Ibrutinib versus Ofatumumab in Previously Treated Chronic Lymphoid Leukemia
|New England Journal of Medicine|2014|1.6k
Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2015|1.6k